In this era of transparency, Medical Affairs is rapidly becoming the new voice of Pharma.
Positioned at the interface between Commercial and R&D, and as the hub of communications with key stakeholders, Medical Affairs is in a prime position to lead Pharma’s transition from merely selling drugs, to playing an integral role in the entire healthcare ecosystem.
The perceived importance of this function is reflected in the growth of its budget and responsibilities. However, the value that Medical Affairs brings to an organisation is notoriously hard to measure. Yet effective measurement can lead to greater efficiency and expertise in bringing stakeholder insights into the company.
Ensuring Optimal Medical Affairs Performance: delivering measurable value is an invaluable resource for anyone interested in the evolution, measurement, and management of Medical Affairs – including Medical Affairs directors; Brand, MSL, and IIT managers; and Global Communications executives.
This up-to-the minute report draws on the expert opinions and experiences of Medical Affairs leaders at top Pharma companies including Astellas, Bayer, Boehringer Ingelheim,and Ferring, and offers numerous case studies detailing best practices that you can bring to your own organisation.
Medical Affairs plays a vital role in meeting rising demands from increasingly varied stakeholders.. However, while nobody disputes the essential nature of their work, there is still a significant benefit in understanding which Medical Affairs activities are the most effective in gathering insights of strategic value. Companies looking for ideas on how to assess the impact of their Medical Affairs programmes and conversations, and how to manage change within the organisation, will find effective answers in this extensive report. Ensuring Optimal Medical Affairs Performance: delivering measurable value will help you to:
Key Questions Answered
Ensuring Optimal Medical Affairs Performance: delivering measurable value answers a wealth of practical questions, such as:
Expert Views Include:
“Most companies are just beginning their journey to fulfil the potential of Medical Affairs. … [Anyone] can see there’s tons of room for improvement. As we get better at it across the globe the need for more precise metrics, in particular, to measure improvement is going to become more and more critical.” Dr. Jeffrey Bloss, vice president, Scientific and Medical Affairs, Astellas
“Most staff rightly feel their work is ethical and scientific at heart, ultimately centred on patients’ interests. So they can easily suspect the company is missing the point of what they do if the approach to performance management is too quantitative and number-driven. This is a completely valid concern that needs to shape what we do about performance management in medical every step of the way.” Michael Andrick, project lead, Medical Affairs Performance Management, Bayer
“As the market place continues to grow in complexity, our customers expect more from us and in particular that we speak to one other internally.” Andy Fuchs, head of Boehringer Ingelheims Global CRM Programme.
Table of Contents
for Ensuring Optimal Medical Affairs Performance: Delivering Measurable Value
2.1.Engine of change
2.2.What is Medical Affairs?
2.3.A rapidly changing field
2.6.Physician Payment Sunshine provisions
2.6.2.New ways of working with physicians
3.Medical Affairs in perspective
3.1.Growth of Medical Affairs
3.1.1.Budget allocation to Medical Affairs
3.1.2.Relative importance of Medical Affairs
3.1.3.Spending breakdown in Medical Affairs
3.1.4.Key findings for best practices
4.Organisation of Medical Affairs
4.1.Maturation along similar lines
4.2.Interacting with brand teams
4.3.Matrix structure at Ferring
4.4.Strategic thinking at Astellas
4.5.Working with the affiliates
5.Measurement of Medical Affairs
6.Assessing relationship quality
6.1.Demonstrating a good job
6.2.Short-term measures of long-term value
10.CRM moves to the cloud
10.1.New CRM challenges
10.2.1.SaaS in the cloud
10.4.Keeping it simple
10.5.The journey continues
Number of Pages
|Title||Date Published||Price from||More Details|
|The ROI of Orphan Drugs-- Ensuring optimal returns (2017)|
Orphan drugs are at the forefront of medical science and offer a chance for the pharma industry to m...
|01 Dec 2017 by FirstWord Pharma||USD $745||More Info|
|Value-based Key Account Management and the NHS — ensuring optimal performance under new rules|
IntroductionCCG commissioners want pharmas money and expertise but on their terms how do you deve...
|01 Jun 2013 by FirstWord Pharma||USD $695||More Info|
|Advisory Committees and Speaker Bureaux - Ensuring Compliance|
IntroductionPharma is faced with increasing constraints on physician participation in its advisory b...
|01 Oct 2012 by FirstWord Pharma||USD $745||More Info|
This report is published by FirstWord Pharma
Download Free Report Summary PDF
Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.
Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.
Accepted Card Types
Buy now using our secure payment system.